Table 3.
PCC delivery before cetuximab maintenance.
| Variable | N = 60 | Paclitaxel 80 mg/m²/week | Carboplatin AUC2/week | Cetuximab 400 mg/m² then 250 mg/m²/week |
|---|---|---|---|---|
| Number of cycles | Median | 9.5 | 9.5 | 10.5 |
| Range | 1–19 | 1–21 | 1–21 | |
| Early discontinuation of treatment (≤8 cycles): | 24 (40) | |||
| - Due to unacceptable toxicities | n (%) | 7 (12) | ||
| - Due to progressive disease | n (%) | 16 (27) | ||
| - Change of treatment (local treatment, etc.) | n (%) | 7 (12) | ||
| Delivery completed (≥16 cycles) | n (%) | 24 (40) | ||
| Patients with dose reductions | n (%) | 19 (32) | 37 (62) | 3 (5) |
| Patients with ≥1 dose held for ≥7 days | n (%) | 27 (45) | 27 (45) | 23 (38) |
| Dose intensity a | Median | 65 | 1.6 | 250 |
| Range | 40–80 | 0.8–2 | 125–250 |
AUC, area under the curve. aDose delivered per week, accounting for treatment delays and dose reductions. Units of measure are as follows: paclitaxel: mg/m²/week; carboplatin: AUC/week; cetuximab: mg/m²/week. The loading dose of cetuximab (i.e., 400amg/m²) was not included in the calculation of dose density.